Human papillomaviruses and skin cancer

Advances in Experimental Medicine and Biology

Volumn 810, Issue , 2014, Pages 192-207

  Smola, Sigrun ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; PROTEIN E6; PROTEIN E7; MEMBRANE PROTEIN; TMC6 PROTEIN, HUMAN; TMC8 PROTEIN, HUMAN; VIRUS PROTEIN;

BETAPAPILLOMAVIRUS; CANCER RISK; DISEASE ASSOCIATION; DNA REPLICATION; EPIDEMIOLOGICAL DATA; EPIDERMODYSPLASIA VERRUCIFORMIS; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENETIC DISORDER; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IN VITRO STUDY; INFECTION RISK; LIFE CYCLE STAGE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RADIATION EXPOSURE; SKIN CANCER; SKIN CARCINOGENESIS; ULTRAVIOLET RADIATION; VIRUS GENE; WART VIRUS; ANIMAL; CLASSIFICATION; GENETIC PREDISPOSITION; GENETICS; HOST PATHOGEN INTERACTION; METABOLISM; MOUSE; MUTATION; PATHOGENICITY; PATHOLOGY; REVIEW; SKIN; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; VIROLOGY;

ANIMALS; BETAPAPILLOMAVIRUS; CARCINOMA, SQUAMOUS CELL; EPIDERMODYSPLASIA VERRUCIFORMIS; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HOST-PATHOGEN INTERACTIONS; HUMANS; MEMBRANE PROTEINS; MICE; MUTATION; SKIN; SKIN NEOPLASMS; VIRAL PROTEINS;

EID: 84907168737     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: None     Document Type: Chapter

References (117)

1. Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen HZ, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010; 401:70-9; PMID:20206957; http://dx.doi.org/10.1016/j.virol.2010.02.002.
2. Schiller JT, Lowy DR. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol2012; 10:681-92; PMID:22961341; http://dx.doi.org/10.1038/nrmicro2872.
3. Jablonska S, Majewski S. Epidermodysplasia verruci form is: immunological and clinical aspects. Curr Top Microbiollmmunol 1994; 186:157-75; PMID:8205840;http://dx.doi.org/10.1007/978-3-642-78487-3_9.
4. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al.; WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens--Part B: biological agents. Lancet Oncol 2009; 10:321-2; PMID: 19350698;http:/dx.doi.org/10.1016/S1470-2045(09)70096-8.
5. Rajagopalan K, Bahru J, Loo DS, Tay CH, Chin KN, Tan KK. Familial epidermodysplasia verruciformis of Lewandowsky and Lutz. Arch Dermatol1972; 105:73-8; PMID:5009624; http://dx.doi.org/10.1001/archderm.1972.01620040045008.
6. Lewandowsky F, Lutz W. Ein Fall einer bisher nicht beschriebenen Hauterkrankung (Epidermodysplasia verruciforrnis). Arch Dermatol Syph 1922; 141:193-203.
7. Lutzner MA.: Epidermodysplasia verruciformis. An autosomal recessive disease characterized by viral warts and skin cancer. A model for viral oncogenesis. Bull Cancer 1978; 65:169-82; PMID:212144.
8. Orth G. Genetics of epidermodysplasia verruciformis: Insights into host defense against papillomaviruses. Semin Immunol 2006; 18:362-74; PMID:17011789; http://dx.doi.org/10.1016/j.smim.2006.07.008.
9. Jablonska S, Milewski B. [Information on epidermodysplasia verruciformis Lewandowsky-Lutz; positive results of auto-and heteroinoculation]. Dermatologica 1957; 115:1-22; PMID:13461537.
10. Ruiter M, van Mullem PJ. Behavior of virus in malignant degeneration of skin lesion in epidermodysplasia verruciforrnis. Jinvest Dermatol 1970; 54:324-31; PMID:4314547; http://dx.doi.org/10.1111/1523-1747.ep12258641.
11. Yabe Y, Okamoto T, Omori S, Tanioku K. Virus particles in epidermodysplasia verruciformis with carcinoma Dermatologica 1969; 139:161-4; PMID:4309378; http://dx.doi.org/10.1159/000253907.
12. Pfister H. Chapter 8: Human papillomavirus and skin cancer. J Natl Cancer Inst Monogr 2003; 31:52-6; PMID: 12807946; http://dx.doi.org/10.1093/oxfordjournals.jncimonographs.a003483.
13. Dell’Oste V, Azzimonti B, De Andrea M, Mondini M, Zavattaro E, Leigheb G, et al. High beta-HPV DNA loads and strong seroreactivity are present in epidermodysplasia verruciformis. J Invest Dermatol 2009; 129:1026-34; PMID: 18923444; http://dx.doi.org/10.1038/jid.2008.317.
14. Borgogna C, Zavattaro E, De Andrea M, Griffin HM, Dell’Oste V, Azzimonti B, et al. Characterization of beta papillomavirus E4 expression in tumours from Epidermodysplasia Verruciforrnis patients and in experimental models. Virology 2012; 423: 195-204; PMID:22217391; http://dx.doi.org/10.1016/j.virol.2011.11.029.
15. Antonsson A, Karanfilovska S, Lindqvist PG, Hansson BG. General acquisition of human papillomavirus infections of skin occurs in early infancy. J Clin Microbiol2003; 41:2509-14; PMID:12791874; http://dx.doi.org/10.1128/JCM.41.6.2509-2514.2003.
16. Weissenborn SJ, De Koning MN, Wieland U, Quint WG, Pfister HJ. Intrafamilial transmission and family­specific spectra of cutaneous betapapillomaviruses. J Virol 2009; 83:811-6; PMID:I8987132; http://dx.doi.org/10.1128/JVI.O1338-08.
17. Antonsson A, Forslund O, Ekberg H, Sterner G, Hansson BG. The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses. J Virol 2000; 74: 11636-41; PMID: 11090162; http://dx.doi.org/10.1128/JVI.74.24.11636-11641.2000.
18. Boxman IL, Berkhout RJ, Mulder LH, Wolkers MC, Bouwes Bavinck JN, Vermeer BJ, et al. Detection of human papillomavirus DNA in plucked hairs from renal transplant recipients and healthy volunteers. J Invest Dermatol 1997; 108:712-5; PMID:9129220; http://dx.doi.org/10.111111523-1747.ep12292090.
19. Jensen P, Hansen S, Møller B, Leivestad T, Pfeffer P, Geiran O, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40: 177-86; PMID:10025742; http://dx.doi.org/10.1016/S0190-9622(99)70185-4.
20. Weissenborn S, Neale RE, Waterboer T, Abeni D, Bavinck JN, Green AC, et al.; EPI-HPV -UV-CA group. Beta-papillomavirus DNA loads in hair follicles of immunocompetent people and organ transplant recipients. Med Microbiol Immunol 2012; 201:117-25; PMID:21792749; http://dx.doi.org/10.1007/s00430-011-0212-3.
21. Karagas MR, Nelson HH, Sehr P, Waterboer T, Stukel TA, Andrew A, et al. Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst 2006; 98:389-95; PMID: 16537831; http://dx.doi.org/10.1093/jnci/djj092.
22. Proby CM, Harwood CA, Neale RE, Green AC, Euvrard S, Naldi L, et al.; EPI-HPV-UV-CA group. A case-control study of betapapillomavirus infection and cutaneous squamous cell carcinoma in organ transplant recipients. Am J Transplant 2011; 11:1498-508; PMID:21718442; http://dx.doi.org/10.1111/j.l600-6143.2011.03589.x.
23. Iannacone MR, Gheit T, Waterboer T, Giuliano AR, Messina JL, Fenske NA, et al. Case-control study of cutaneous human papillomaviruses in squamous cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev 2012; 21:1303-13; PMID:22707711; http://dx.doi.org/10.1158/1055-9965.EPI-12-0032.
24. Karagas MR, Waterboer T, Li Z, Nelson HH, Michael KM, Bavinck JN, et al.; New Hampshire Skin Cancer Study Group. Genus beta human papillomaviruses and incidence of basal cell and squamous cell carcinomas of skin: population based case-control study. BMJ 2010; 341:c2986; PMID:20616098; http://dx.doi.org/10.1136/bmj.c2986.
25. Weissenborn SJ, Nindl I, Purdie K, Harwood C, Proby C, Breuer J, et al. Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J Invest Dermatol 2005; 125:93-7; PMID: 15982308; http://dx.doi.org/10.1111/j.0022-202X.2005.23733.x.
26. Arron ST, Ruby JG, Dybbro E, Ganem D, Derisi JL. Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma J Invest Dermatol 2011; 131:1745-53; PMID:21490616; http://dx.doi.org/10.1038/jid.2011.91.
27. Haller K, Stubenrauch F, Pfister H. Differentiation-dependent transcription of the epidermodysplasia verruciformis-associated human papillomavirus type 5 in benign lesions. Virology 1995; 214:245-55; PMID:8525623; http://dx.doi.org/10.1006/viro.1995.0028.
28. Muller M, Jacob Y, Jones L, Weiss A, Brino L, Chantier T, et al. Large scale genotype comparison of human papillomavirus E2-host interaction networks provides new insights for e2 molecular functions. PLoS Pathog 2012; 8:e1002761; PMID:22761572; http://dx.doi.org/10.1371/journal.ppat.1002761.
29. Oldak M, Smola H, Aumailley M, Rivero F, Pfister H, Smola-Hess S. The human papillomavirus type 8 E2 protein suppresses beta4-integrin expression in primary human keratinocytes. J Virol 2004; 78: 10738-46; PMID: 15367640; http://dx.doi.org/10.1128/JVI.78.19.10738-10746.2004.
30. Oldak M, Maksym RB, Sperling T, Yaniv M, Smola H, Pfister HJ, et al. Human papillomavirus type 8 E2 protein unravels JunB/Fra-1 as an activator of the beta4-integrin gene in human keratinocytes. J Virol 2010; 84:1376-86; PMID: 19923172; http://dx.doi.org/10.1128/JV1.01220-09.
31. Hadaschik D, Hinterkeuser K, Oldak M, Pfister HJ, Smola-Hess S. The Papillomavirus E2 protein binds to and synergizes with CIEBP factors involved in keratinocyte differentiation. J Virol 2003; 77:5253-65; PMID: 12692227; http://dx.doi.org/10.1128/JVI.77.9.5253-5265.2003.
32. Oliveira JG, Coif LA, McBride AA. Variations in the association of papillomavirus E2 proteins with mitotic chromosomes. Proc Natl Acad Sci US A 2006; 103:1047-52; PMID:l6415162; http://dx.doi.org/10.1073/pnas.0507624103.
33. Sakakibara N, Mitra R, McBride AA. The papillomavirus El helicase activates a cellular DNA damage response in viral replication foci. J Virol 2011; 85:8981-95; PMID:21734054; http://dx.doi.org/10.1128/JV1.00541-11.
34. McBride AA, Sakakibara N, Stepp WH, Jang MK. Hitchhiking on host chromatin: how papillomaviruses persist. Biochim Biophys Acta 2012;1819:820-5.
35. White EA, Kramer RE, Tan MJ, Hayes SD, Harper JW, Howley PM. Comprehensive analysis of host cellular interactions with human papillomavirus E6 proteins identifies new E6 binding partners and reflects viral diversity. J Virol 2012; 86:13174-86; PMID:23015706; http://dx.doi.org/10.1128/JVI.02172-12.
36. Ruhland A, de Villiers EM. Opposite regulation of the HPV 20-URR and HPV 27-URR promoters by ultraviolet irradiation and cytokines. Int J Cancer 2001; 91:828-34; PMID:ll275987; http://dx.doi.org/10.1002/1097-0215(200002)9999:9999<: AID-IJC 1129>3.O.C0;2-B.
37. Oldak M, Tolzmann L, Wnorowski A, Podgórska MJ, Silling S, Lin R, et al. Differential regulation of human papillomavirus type 8 by interferon regulatory factors 3 and 7. J Virol 2011; 85: 178-88; PMID:20980500; http://dx.doi.org/10.1128/JV1.00998-10.
38. Akgül B, Lemme W, García-Escudero R, Storey A, Pfister HJ. UV-B irradiation stimulates the promoter activity of the high-risk, cutaneous human papillomavirus 5 and 8 in primary keratinocytes. Arch Virol 2005; 150:145-51; PMID: 15654507; http://dx.doi.org/10.1007/s00705-004-0398-4.
39. Kim TK, Kim T, Kim TY, Lee WG, Yim J. Chemotherapeutic DNA-damaging drugs activate interferon regulatory factor-7 by the mitogen-activated protein kinase kinase-4-cJun NH2-terminal kinase pathway. Cancer Res 2000; 60:1153-6; PMID:10728664.
40. Takaoka A, Tamura T, Taniguchi T. Interferon regulatory factor family of transcription factors and regulation of oncogenesis. Cancer Sci 2008; 99:467-78; PMID: 18190617;http://dx.doi.org/10.1111/j.1349-7006.2007.00720.x.
41. Ramoz N, Rueda LA, Bouadjar B, Favre M, Orth G. A susceptibility locus for epidermodysplasia verruciformis, an abnormal predisposition to infection with the oncogenic human papillomavirus type 5, maps to chromosome 17qter in a region containing a psoriasis locus. J Invest Dermatol 1999; 112:259-63; PMID: 10084299; http://dx.doi.org/10.1046/j.1523-1747.1999.00536.x.
42. Ramoz N, Taïeb A, Rueda LA, Montoya LS, Bouadjar B, Favre M, et al. Evidence for a nonallelic heterogeneity of epidermodysplasia verruciformis with two susceptibility loci mapped to chromosome regions 2p21-p24 and 17q 25. J Invest Dermatol 2000; 114:1148-53; PMID:10844558; http://dx.doi.org/10.1046/j.1523-1747.2000.00996.x.
43. Ramoz N, Rueda LA, Bouadjar B, Montoya LS, Orth G, Favre M. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 2002; 32:579-81; PMID:12426567; http://dx.doi.org/10.1038/ng 1044.
44. Palmiter RD, Findley SD. Cloning and functional characterization of a mammalian zinc transporter that confers resistance to zinc. EMBO J 1995; 14:639-49; PMID: 7882967.
45. Lazarczyk M, Pons C, Mendoza JA, Cassonnet P, Jacob Y, Favre M. Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses. J Exp Med 2008;205: 35-42; PMID: 18158319; http://dx.doi.org/10.1084/jem.20071311.
46. Wang SS, Gonzalez P, Yu K, Porras C, Li Q, Safaeian M, et al. Common genetic variants and risk for HPV persistence and progression to cervical cancer. PLoS One 2010; 5:e8667; PMID:20084279; http://dx.doi.org/10.1371/journal.pone.0008667.
47. Pyrhönen S, Jablonska S, Obalek S, Kuismanen E. Immune reactions in epidermodysplasia verruciformis. Br J Dermatol 1980; 102:247-54; PMID:6245674;http://dx.doi.org/10.1111/j.1365-2133.1980.tb08136.x.
48. Gliński W, Jablonska S, Langner A, Obalek S, Haftek M, Proniewska M. Cell-mediated immunity in epidermodysplasia verruciformis. Dermatologica 1976; 153:218-27; PMID: 1017532; http://dx.doi.org/10.1159/ 000251060.
49. Crequer A, Troeger A, Patin E, Ma CS, Picard C, Pedergnana V, et al. Human RHOH deficiency causes T cell defects and susceptibility to EV-HPV infections. J Clin Invest 2012; 122:3239-47; PMID:22850876; http://dx.doi.org/10.1172/JCI62949.
50. Crequer A, Picard C, Pedergnana V, Lim A, Zhang SY, Abel L, et al. EVER2 deficiency is associated with mild T-cell abnormalities. J Clin lmmunol 2013; 33:14-21; PMID:22903682; http://dx.doi.org/10.10071s10875-012-9749-1.
51. Crequer A, Picard C, Patin E, D’Amico A, Abhyankar A, Munzer M, et al. Inherited MSTl deficiency underlies susceptibility to EV-HPV infections. PLoS One 2012; 7:e44010; PMID:22952854; http://dx.doi.org/10.1371/journal.pone.0044010.
52. Mermet L, Guerrini JS, Cairey-Remonnay S, Drobacheff C, Faivre B, Gaillard M, et al. Cervical intraepithelial neoplasia associated with epidermodysplasia verruciformis HPV in an HIV -infected patient: a manifestation of immune restoration syndrome. Eur J Dermatol 2007; 17:149-52; PMID: 17337400.
53. Huiras E, Preda V, Maurer T, Whitfeld M. Cutaneous manifestations of immune reconstitution inflammatory syndrome. Curr Opin HIV AIDS 2008; 3:453-60; PMID:I9373005; http://dx.doi.org/10.1097/COH.Ob013e328302cefe.
54. da Silva LC, Miranda AE, Ferreira LC, da Silva RM Jr., Mira MT, Talhari C, et al. Post-ART epidermodysplasia verruciformis in a patient with AIDS. J lnt Assoc Physicians AIDS Care (Chic) 2010; 9: 10-4; PMID:20071592; http:/ldx.doi.org/10.1177/1545109709355709.
55. Michael KM, Waterboer T, Pfister H, Gariglio M, Majewski S, Favre M, et al. Seroreactivity of38 human papillomavirus types in epidermodysplasia verruciformis patients, relatives, and controls. J Invest Dermatol 2010; 130:841-8; PMID: 19924140; http://dx.doi.org/10.1038/jid.2009.356.
56. Sperling T, Ołdak M, Walch-Rückheim B, Wickenhauser C, Doorbar J, Pfister H, et al. Human papillomavirus type 8 interferes with anovel C/EBP β-mediated mechanism of keratinocyte CCL20 chemokine expression and Langerhans cell migration. PLoS Pathog 2012; 8:e1002833; PMID:22911498; http://dx.doi.org/10.13711journal.ppat.1002833.
57. Cooper KD, Androphy EJ, Lowy D, Katz SI. Antigen presentation and T-cell activation in epidermodysplasia verruciformis. J Invest Dermatol 1990; 94:769-76; PMID:2162366; http://dx.doi.org/10.111111523-1747.ep12874631.
58. van Voorst Vader PC, de Jong MC, Blanken R, Kallenberg CG, Vermey A, Scheres JM. Epidermodysplasia verruciformis: Langerhans cells, immunologic effect of retinoid treatment and cytogenetics. Arch Dermatol Res 1987; 279:366-73; PMID:3499869; http://dx.doi.org/10.1007/BF00412621.
59. Stoitzner P, Tripp CH, Eberhart A, Price KM, Jung JY, Bursch L, et al. Langerhans cells cross-present antigen derived from skin. Proc Natl Acad Sci U SA 2006; 103:7783-8; PMID: 16672373; http://dx.doi.org/10.1073/pnas.05093071 03.
60. Dandie GW, Clydesdale GJ, Jacobs I, Muller HK. Effects of UV on the migration and function of epidermal antigen presenting cells. Mutat Res 1998;422: 147-54; PMID:9920439; http://dx.doi.org/10.1016/S0027-5107(98)00186-9.
61. Dieu-Nosjean MC, Massacrier C, Homey B, Vanbervliet B, Pin JJ, Vicari A, et al. Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. J Exp Med 2000; 192:705-18; PMID:10974036; http://dx.doi.org/10.1084/jem.192.5.705.
62. Le Borgne M, Etchart N, Goubier A, Lira SA, Sirard JC, van Rooijen N, et al. Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CDS+ T cell crosspriming in vivo. Immunity 2006; 24:191-201; PMID:16473831; http://dx.doi.org/10.1016/j.immuni.2006.01. 005.
63. Charbonnier AS, Kohrgruber N, Kriehuber E, Stingl G, Rot A, Maurer D. Macrophage inflammatory protein 3alpha is involved in the constitutive trafficking of epidermallangerhans cells. J Exp Med 1999; 190:1755-68; PMID: 10601351; http://dx.doi.org/10.1084/jem.190.12. 1755.
64. Sinha RP, Häder DP. UV-induced DNA damage and repair: a review. Photochem Photobiol Sci 2002; 1:225-36; PMID: 12661961; http://dx.doi.org/10.1 039/b201230h.
65. Roshan A, Jones PH. Chronic low dose UV exposure and p53 mutation: tilting the odds in early epidermal preneoplasia? Int J Radiat Biol 2012; 88:682-7; PMID:22671441; http:/ldx.doi.org/10.3109/09553002.2012.699697.
66. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci US A 1991; 88:10124-8; PMID: 1946433; http://dx.doi.org/10.1073/pnas.88.22.10124.
67. Amundson SA, Myers TG, Fomace AJ Jr. Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene 1998; 17:3287-99; PMID:9916991; http://dx.doi.org/10.1038/sj.onc.l 202576.
68. Ziegler A, Leffell DJ, Kunala S, Sharma HW, Gailani M, Simon JA, et al. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci U S A 1993; 90:4216-20; PMID:8483937; http://dx.doi.org/10.1073/pnas.90.9.4216.
69. Ziegler A, Jonason AS, Leffell DJ, Simon JA, Sharma HW, Kimmelman J, et al. Sunburn and p53 in the onset of skin cancer. Nature 1994; 372:773-6; PMID:7997263; http://dx.doi.org/10.1038/372773a 0.
70. Padlewska K, Ramoz N, Cassonnet P, Riou G, Barrois M, Majewski S, et al. Mutation and abnormal expression of the p53 gene in the viral skin carcinogenesis ofepidermodysplasia verruciformis. J Invest Dermatol 2001; 117:935-42; PMID: 11676835; http://dx.doi.org/10.1046/j.0022-202x.2001.01515.x.
71. Huibregtse JM, Scheffner M, Howley PM. Cloning and expression of the eDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p 53. Mol Cell Bioi 1993; 13:775-84; PMID: 8380895.
72. Huibregtse JM, Scheffuer M, Howley PM. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 1991; 10:4129-35; PMID:1661671.
73. Elbel M, Carl S, Spadema S, Iftner T. A comparative analysis of the interactions of the E6 proteins from cutaneous and genital papillomaviruses with p53 and E6AP in correlation to their transforming potential. Virology 1997; 239:132-49; PMID:9426453; http://dx.doi.org/10.1006/viro.1997.8860.
74. Steger G, Pfister H. In vitro expressed HPV 8 E6 protein does not bind p 53. Arch Virol 1992; 125:355-60; PMID: 1642560; http://dx.doi.org/10.1007/BF01309654.
75. Schaper ID, Marcuzzi GP, Weissenborn SJ, Kasper HU, Dries V, Smyth N, et al. Development of skin tumors in mice transgenic for early genes of human papillomavirus type 8. Cancer Res 2005; 65:1394-400; PMID: 15735026; http://dx.doi.org/10.1158/0008-5472.CAN-04-3263.
76. De Andrea M, Rittà M, Landini MM, Borgogna C, Mondini M, Kern F, et al. Keratinocyte-specific stat3 heterozygosity impairs development of skin tumors in human papillomavirus 8 transgenic mice. Cancer Res 2010; 70:7938-48; PMID:20876801; http://dx.doi.org/10.1158/0008-5472.CAN-10-1128. 77.
77. Schröer N, Palme J, Walch B, Wickenhauser C, Smola S. Molecular pathobiology of human cervical high­ grade lesions: paracrine STAT3 activation in tumor-instructed myeloid cells drives local MMP-9 expression. Cancer Res 2011; 71:87-97; PMID:21199798; http://dx.doi.org/10.1158/0008-5472.CAN-10-2193.
78. Marcuzzi GP, Hutbauer M, Kasper HU, Weissenborn SJ, Smola S, Pfister H. Spontaneous tumour development in human papillomavirus type 8E6transgenic mice and rapid induction by UV-light exposure and wounding. J Gen Virol 2009;90:2855-64. Epub 009 Aug 19.
79. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7; PMID: 12490959; http://dx.doi.org/10.1038/nature 01322.
80. Pfefferle R, Marcuzzi GP, Akgul B, Kasper HU, Schulze F, Haase I, Wickenhauser C, Pfister H. The human papillomavirus type 8 E2 protein induces skin tumors in transgenic mice. J Invest Dermatol 2008;128:2310-5. Epub 008 Apr 10.
81. Dvorak HF. Tumors: wounds that donot heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315:1650-9; PMID:3537791; http://dx.doi.org/10.1056/NEJM 198612253152606.
82. Viarisio D, Mueller-Decker K, Kloz U, Aengeneyndt B, Kopp-Schneider A, Gröne HJ, et al. E6 and E7 from beta HPV 38 cooperate with ultraviolet light in the development of actinic keratosis-like lesiom and squamous cell carcinoma in mice. PLoS Pathog 2011; 7:e1002125; PMID:21779166; http://dx.doi.org/10.137l/journal.ppat.1002125.
83. Michel A, Kopp-Schneider A, Zentgraf H, Gruber AD, de Villiers EM. E6/E7 expression of human papillomavirus type 20 (HPV-20) and HPV -27 influences proliferation and differentiation of the skin in UV-irradiated SKH-hrl transgenic mice. J Virol 2006; 80:11153-64; PMID:16971438; http://dx.doi.org/10.1128/JVI.00954-06.
84. Dong W, Kloz U, Accardi R, Caldeira S, Tong WM, Wang ZQ, et al. Skin hyperproliferation and susceptibility to chemical carcinogenesis in transgenic mice expressing E6 and E7 of human papillomavirus type 38. J Virol 2005; 79: 14899-908; PMID: 16282489; http://dx.doi.org/10.1128/JVI.79.23.14899-14908.2005.
85. Yamashita T, Segawa K, Fujinaga Y, Nishikawa T, Fujinaga K. Biological and biochemical activity of E7 genes of the cutaneous human papillomavirus type 5 and 8. Oncogene 1993; 8:2433-41; PMID: 8395681.
86. Massimi P, Thomas M, Bouvard V, Ruberto I, Campo MS, Tommasino M, et al. Comparative transforming potential of different human papillomaviruses associated with non-melanoma skin cancer. Virology 2008; 371:374-9; PMID: 17997466; http://dx.doi.org/10.1016/j.virol.2007.10.015.
87. Schmitt A, Harry JB, Rapp B, Wettstein FO, Ifiner T. Comparison of the properties of the E6 and E7 genes ol low-and high-risk cutaneous papillomaviruses reveals strongly transforming and high Rb-binding activity for the E7 protein of the low-risk human papillomavirus type 1. J Virol 1994; 68:7051-9; PMID: 7933087.
88. Caldeira S, Zehbe I, Accardi R, Malanchi I, Dong W, Giarrè M, et al. The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties. J Virol 2003; 77:2195-206; PMID: 12525654; http://dx.doi.org/10.1128/JVI.77.3.2195-2206.2003.
89. Comet I, Bouvard V, Campo MS, Thomas M, Banks L, Gissmann L, et al. Comparative analysis ol transforming properties of E6 and E7 from different beta human papillomavirus types. J Virol 2012; 86:2366-70; PMID:22171257; http://dx.doi.org/10.1128/JVI.06579-11.
90. Brimer N, Lyons C, Wallberg AE, Vande Pol SB. Cutaneous papillomavirus E6 oncoproteins associate with MAML 1to repress transactivation and NOTCH signaling. Oncogene 2012;31:4639-46; PMID:22249263; http://dx.doi.org/10.1038/onc.2011.589.
91. Tan MJ, White EA, Sowa ME, Harper JW, Aster JC, Howley PM. Cutaneous β-human papillomavirus E6 proteins bind Mastermind-like coactivators and repress Notch signaling. Proc Natl Acad Sci USA 2012; 109:E1473-80; PMID:2254 7818; http://dx.doi.org/10.1073/pnas.l205991109.
92. Rozenblatt-Rosen O, Deo RC, Padi M, Adelmant G, Calderwood MA, Rolland T, et al. Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature 2012; 487:491-5; PMID:22810586; http://dx.doi.org/10.1038/naturell 288.
93. Meyers JM, Spangle JM, Munger K. The HPV8 E6 protein interferes with NOTCH activation during keratinocyte differentiation. J Virol 2013; PMID:23365452; http://dx.doi.org/10.1128/JVI.02527-12.
94. Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, et al. Notch1 functions as atumor suppressor in mouse skin. Nat Genet 2003; 33:416-21; PMID:12590261; http://dx.doi.org/10.1038/ngl 099.
95. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p 53. Cell 1993; 75:495-505; PMID:8221889; http://dx.doi.org/10.1016/0092-8674(93)90384-3.
96. Scheffner M, Wemess BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16and 18promotes the degradationofp 53. Cell 1990; 63: 1129-36; PMID:2175676; http://dx.doi.org/10.1016/0092-8674(90)90409-8.
97. Wemess BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p 53. Science 1990; 248:76-9; PMID:2157286; http://dx.doi.org/10.1126/science. 2157286.
98. Giampieri S, Storey A. Repair of UV-induced thymine dimers is compromised in cells expressing the E6 protein from human papillomaviruses types 5 and 18. Br J Cancer 2004; 90:2203-9; PMID:15150558.
99. Muschik D, Braspenning-Wesch I, Stockfleth E, Rösl F, Hofmann TG, Nindl I. Cutaneous HPV23 E6 prevents p53 phosphorylation through interaction with HIPK 2. PLoS One 2011; 6:e27655; PMID:2211 0707; http://dx.doi.org/10.1371/journal.pone.0027655.
100. Accardi R, Dong W, Smet A, Cui R, Hautefeuille A, Gabet AS, et al. Skin human papillomavirus type 38 alters p53 functions by accumulation of delta Np 73. EMBO Rep 2006; 7:334-40; PMID:16397624; http://dx.doi.org/10.1038/sj.embor.7400615.
101. Gabet AS, Accardi R, Bellopede A, Popp S, Boukamp P, Sylla BS, et al. Impairment of the telomere/telomerase system and genomic instability are associated with keratinocyte immortalization induced by the skin human papillomavirus type 38. FASEB J 2008; 22:622-32; PMID: 17898088; http://dx.doi.org/10.1096/fj.07-8389com
102. Bedard KM, Underbrink MP, Howie HL, Galloway DA. The E6 oncoproteins from human betapapillomaviruses differentially activate telomerase through an E6AP-dependent mechanism and prolong the lifespan of primary keratinocytes. J Virol 2008; 82:3894-902; PMID: 18256157; http://dx.doi.org/10.1128/JVI.01818-07.
103. Jackson S, Harwood C, Thomas M, Banks L, Storey A. Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev 2000; 14:3065-73; PMID:11114894; http://dx.doi.org/10.1101/gad.182100.
104. Underbrink MP, Howie HL, Bedard KM, Koop JI, Galloway DA. E6 proteins from multiple human betapapillomavirus types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation. J Virol 2008; 82: 10408-17; PMID: 18715924; http://dx.doi.org/10.1128/JVI.00902-08.
105. Howie HL, Koop JI, Weese J, Robinson K, Wipf G, Kim L, et al. Beta-HPV 5 and 8 E6 promote p300 degradation by blocking AKT/p300 association. PLoS Pathog 2011; 7:e1002211; PMID:21901101; http://dx.doi.org/10.1371/journal.ppat.1002211.
106. Müller-Schiffinann A, Beckmann J, Steger G. The E6 protein of the cutaneous human papillomavirus type 8 can stimulate the viral early and late promoters by distinct mechanisms. J Virol 2006; 80:8718-28; PMID: 16912319; http://dx.doi.org/l0.1128/JVI.00250-06.
107. Muench P, Probst S, Schuetz J, Leiprecht N, Busch M, Wesselborg S, et al. Cutaneous papillomavirus E6 proteins must interact with p300 and block p53-mediated apoptosis for cellular immortalization and tumorigenesis. Cancer Res 2010; 70:6913-24; PMID:20663910; http:/ldx.doi.org/10.1158/0008-5472.CAN-10-1307.
108. Wallace NA, Robinson K, Howie HL, Galloway DA. HPV 5 and 8 E6 abrogate ATR activity resulting in increased persistence of UVB induced DNA damage. PLoS Pathog 2012; 8:e1002807; PMID:22807682; http://dx.doi.org/10.13711journal.ppat.1002807.
109. White EA, Sowa ME, Tan MJ, Jeudy S, Hayes SD, Santha S, et al. Systematic identification of interactions between host cell proteins and E7 oncoproteins from diverse human papillomaviruses. Proc Natl Acad Sci USA 2012; 109:E260-7; PMID:22232672; http://dx.doi.org/10.1073/pnas.1116776109.
110. Buitrago-Pérez A, Hachirni M, Dueñas M, Lloveras B, Santos A, Holguín A, et al. A humanized mouse model of HPV-associated pathology driven by E7 expression. PLoS One 2012; 7:e41743; PMID:22911850; http://dx.doi.org/10.1371/journal.pone. 0041743.
111. Shephard P, Martin G, Smola-Hess S, Brunner G, Krieg T, Smola H. Myofibroblast differentiation is induced inkeratinocyte-fibroblast co-cultures and is antagonistically regulated by endogenous transforming growth factor-beta and interleukin-1. Am J Pathol 2004; 164:2055-66; PMID:15161640; http://dx.doi.org/10.1016/S0002-9440(10)63764-9.
112. Lee DK, Kim BC, Kim IY, Cho EA, Satterwhite DJ, Kim SJ. The human papilloma virus E7 oncoprotein inhibits transforming growth factor-beta signaling by blocking binding of the Smad complex to its target sequence. J Biol Chem 2002;277:38557-64; PMID:12145312;http://dx.doi.org/10.1074/jbc.M 206786200.
113. Habig M, Smola H, Dole VS, Derynck R, Pfister H, Smola-Hess S. E7 proteins from high-and low-risk human papillomaviruses bind to TGF-beta-regulated Smad proteins and inhibit their transcriptional activity. Arch Virol 2006; 151:1961-72; PMID: 16710631; http://dx.doi.org/10.1007/s00705-006-0768-l.
114. Smola-Hess S, Pahne J, Mauch C, Zigrino P, Smola H, Pfister HJ. Expression of membrane type 1 matrix metalloproteinase in papillomavirus-positive cells: role of the human papillomavirus (HPV) 16and HPV8 E7 gene products. J Gen Virol 2005; 86: 1291-6; PMID: 15831939; http://dx.doi.org/10.1099/vir.0.80551-0.
115. Stemlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17:463-516; PMID:11687497; http://dx.doi.org/l0.1146/annurev.cellbio.17.1.463.
116. Akgül B, García-Escudero R, Ghali L, Pfister HJ, Fuchs PG, Navsaria H, et al. The E7 protein of cutaneous human papillomavirus type 8 causes invasion of human keratinocytes into the dermis in organotypic cultures of skin. Cancer Res 2005; 65:2216-23; PMID:l5781634; http://dx.doi.org/10.1158/0008-5472.CAN-04-1952.
117. Akgül B, Pfefferle R, Marcuzzi GP, Zigrino P, Krieg T, Pfister H, et al. Expression of matrix metalloproteinase (MMP)-2, MMP-9, MMP-13, and MTl-MMP in skin tumors ofhuman papillomavirus type 8transgenic mice. Exp Dermato1 2006; 15:35-42; PMID: 16364029; http://dx.doi.org/10.1111j.0906-6705.2005.00387.X